{"id":50,"date":"2015-10-21T11:16:40","date_gmt":"2015-10-21T10:16:40","guid":{"rendered":"http:\/\/blog.u-bourgogne.fr\/list-maps\/?page_id=50"},"modified":"2016-06-02T14:47:20","modified_gmt":"2016-06-02T13:47:20","slug":"biofilm-control","status":"publish","type":"page","link":"https:\/\/blog.ube.fr\/list-maps\/consortium\/beneficiaries\/biofilm-control\/","title":{"rendered":"BioFilm Control"},"content":{"rendered":"

\"logobio\"<\/a><\/p>\n

PRESENTATION OF THE COMPANY<\/strong><\/p>\n

BioFilm Control is a Biotechnology R&D company, formed in 2004, which has developed one-of-a-kind proprietary technology using magnetisable microbeads, protected by 7 patents and 9 trademarks. This technology detects the biofilm behaviour of microorganisms and was automated in 2009. This is the only \u201cbiofilm\u201d technology in Medical Analysis Laboratories (Public or Private institutions).
\nBioFilm Control markets BioFilm Ring Test\u00ae and Antibiofilmogram\u00ae kits in 96-well plate format for research use only. The Antibiofilmogram\u00ae kits study the susceptibility of bacteria to antibiotics, both in planktonic and biofilm populations. Three panels of 11 antibiotics are available, defined for Staphylococcus aureus (in Bone & joint infections and Diabetic Foot), Escherichia coli (in Urinary Tract Infections), Pseudomonas aeruginosa (in Cystic fibrosis and Pulmonary infections). Clinical protocols are under way and the first MD-IVD versions with CE marking are scheduled for 2017.
\nThe company also operates its biofilm expertise under R&D (pharmaceutical industry \u2013 human health and veterinary applications-, cosmetics industry, food, hygiene, etc).
\nBioFilm Control currently employs 11 people working in premises of 400m\u00b2, 90m\u00b2 of which dedicated to a P2 laboratory. The team is made up of 2 directors-researchers, one Project Manager, one administrative assistant and 7 engineers\/technicians. BioFilm Control is also backed by a Scientific Committee made up of: Prof. Kaplan, Ph.D. American University, Washington (inventor of the first antibiofilm agent, Dispersin B), Pr McArthur, M.D., Ph.D., University of Missouri, Kansas City (expert on Mycobacterium tuberculosis, on HIV, on Diagnostic tests), Prof. Tulkens, Univ. Catholique Louvain (one of the founders of EUCAST), Dr Jehl, CHU Strasbourg (Chairman of the French Antibiogram Committee), Dr Laurent, AP-HP Lyon (reference for Bone & Joint Infections), Prof. Lavigne and Prof. Sotto, CHU N\u00eemes (Diabetic Foot reference)\u2026<\/p>\n

Website:<\/strong> http:\/\/www.biofilmcontrol.com\/en\/<\/a><\/p>\n

ROLE IN THE PROJECT<\/strong><\/p>\n

Sub-project 11: Development of innovative tools for rapid phenotypic characterisation of intraspecific diversity<\/a><\/p>\n

STAFF INVOLVED<\/strong><\/p>\n

Thierry BERNARDI<\/strong><\/p>\n

\"tb\"<\/a><\/p>\n

Thierry BERNARDI is the founder of BioFilm Control as well as the inventor of the BioFilm Ring Test\u00ae<\/p>\n

Education<\/strong><\/p>\n

Pharm.D in 1991 from the University of Montpellier (France)<\/p>\n

Professional and teaching experience<\/strong><\/p>\n

Prior to founding BioFilm Control, he held several technical, general management and business development positions intechnical, general management and business development positions in start-ups (Nucleica, GeneSystems) and multinational companies (SANOFI, Perkin Elmer, Applied Biosystems).<\/p>\n

Research Interests<\/strong><\/p>\n

R&D in Biotechnologies, Diagnostics and Pharmacy.<\/p>\n

Main publications:<\/strong><\/p>\n